Pay in 4 interest-free payments of $6.06 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
JP Richie Jr, S Nichenametla, W Neidig, et al
The results showed no significant differences in any of the indicators, indicating that FOXO4-DRI treatment did not adversely affect liver or kidney function or cell viability in mice (Supplementary Figures S2AC)
The FDA states that the agency would consider taking action against a compounder for compounding drug products with this bulk drug substance
Neither peptide has progressed to human clinical trials, keeping both firmly in the preclinical research domain
US$ 24.93
US$ 22.18
US$ 27.08
US$ 28.79
US$ 26.89
